• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2025 Financial Results

    10/21/25 8:00:00 AM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PTCT alert in real time by email

    WARREN, N.J., Oct. 21, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today that the company will host a webcast conference call to report its third quarter 2025 financial results and provide an update on the company's business and outlook on Tuesday, November 4, at 4:30 p.m. ET.

    PTC Therapeutics, Inc. Logo (PRNewsfoto/PTC Therapeutics, Inc.)

    To access the call by phone, please click here to register, and you will be provided with dial-in details. To avoid delays, we recommend that participants dial in for the conference call 15 minutes before the start of the call. The webcast conference call can be accessed on the Investors section of the PTC website at https://ir.ptcbio.com/events-presentations. A replay of the call will be available approximately two hours after completion of the call and will be archived on the company's website for 30 days.

    ABOUT PTC THERAPEUTICS, INC.

    PTC is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of clinically differentiated medicines for children and adults living with rare disorders. PTC is advancing a robust and diversified pipeline of transformative medicines as part of its mission to provide access to best-in-class treatments for patients with unmet medical needs. The company's strategy is to leverage its scientific expertise and global commercial infrastructure to optimize value for patients and other stakeholders. To learn more about PTC, please visit www.ptcbio.com and follow on Facebook, X, and LinkedIn.

    For more information, please contact:

    Investors:

    Ellen Cavaleri

    +1 (615) 618-8228

    ecavaleri@ptcbio.com

    Media:

    Jeanine Clemente

    +1 (908) 912-9406

    jclemente@ptcbio.com

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ptc-therapeutics-to-host-conference-call-to-discuss-third-quarter-2025-financial-results-302589963.html

    SOURCE PTC Therapeutics, Inc.

    Get the next $PTCT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PTCT

    DatePrice TargetRatingAnalyst
    5/27/2026$85.00Hold → Buy
    Jefferies
    5/8/2026$90.00Hold → Buy
    TD Cowen
    4/10/2026$108.00Outperform
    Raymond James
    1/28/2026$119.00Overweight
    Barclays
    12/1/2025$91.00Outperform → Sector Perform
    RBC Capital Mkts
    10/20/2025$73.00Overweight
    Wells Fargo
    6/17/2025$80.00Buy
    Truist
    5/9/2025$68.00Neutral → Buy
    BofA Securities
    More analyst ratings

    $PTCT
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by PTC Therapeutics Inc.

    SCHEDULE 13G/A - PTC THERAPEUTICS, INC. (0001070081) (Subject)

    5/15/26 1:46:16 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by PTC Therapeutics Inc.

    10-Q - PTC THERAPEUTICS, INC. (0001070081) (Filer)

    5/7/26 4:32:44 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PTC Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - PTC THERAPEUTICS, INC. (0001070081) (Filer)

    5/7/26 4:09:45 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PTCT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

    – First quarter 2026 total revenue of $273 million, including $226 million of product revenue, supporting full-year 2026 guidance raise –   – Global Sephience™ (sepiapterin) launch momentum continues with first quarter 2026 revenue of $125 million, representing 36% quarter-over-quarter growth – – Positive topline results from 24-month interim analysis of PIVOT-HD extension study of votoplam, supporting ongoing global Phase 3 INVEST-HD study and potential regulatory interactions – – Open-label vatiquinone registration study to be initiated in Q3 2026 based on FDA feedback –WARREN, N.J., May 7, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ:PTCT) today announced a corporate update and fi

    5/7/26 4:01:00 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PTC Therapeutics to Participate in Upcoming Investor Conferences

    WARREN, N.J., May 4, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced that its executives will speak at the following conferences: Bank of America Securities Health Care Conference 2026Tuesday, May 12 at 8:40 a.m. PDT / 11:40 a.m. EDTRBC Capital Markets 2026 Global Healthcare ConferenceWednesday, May 20 at 10 a.m. EDTGoldman Sachs 47th Annual Global Healthcare ConferenceTuesday, June 9 at 9:20 a.m. EDTThe presentations will be webcast live on the Events and Presentations page under the Investor section of PTC Therapeutics' website at https://ir.ptcbio.co

    5/4/26 8:00:00 AM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PTC Therapeutics Reports Positive Topline Results from Month 24 Interim Analysis of PIVOT-HD Extension Study of Votoplam

    - Dose-dependent benefit on cUHDRS in Stage 2 participants compared to matched natural history cohort, with 52% slowing at 10 mg dose -- Continued evidence of favorable safety profile - - Novartis initiated global Phase 3 INVEST-HD study of votoplam -- PTC will host a conference call to discuss results today, April 28, at 4:30 pm ET - WARREN, N.J., April 28, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today reported positive topline results from the 24-month interim analysis of the PIVOT-HD long-term extension study, with favorable dose-dependent effects on disease progression for Stage 2 Huntington's disease (HD) patients following 24 months of votoplam treatment compared to a

    4/28/26 4:05:00 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PTCT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    PTC Therapeutics upgraded by Jefferies with a new price target

    Jefferies upgraded PTC Therapeutics from Hold to Buy and set a new price target of $85.00

    5/27/26 9:06:00 AM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PTC Therapeutics upgraded by TD Cowen with a new price target

    TD Cowen upgraded PTC Therapeutics from Hold to Buy and set a new price target of $90.00

    5/8/26 8:42:12 AM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Raymond James initiated coverage on PTC Therapeutics with a new price target

    Raymond James initiated coverage of PTC Therapeutics with a rating of Outperform and set a new price target of $108.00

    4/10/26 8:34:55 AM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PTCT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Gravier Pierre bought $198,736 worth of shares (7,700 units at $25.81), increasing direct ownership by 30% to 33,700 units (SEC Form 4)

    4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)

    12/14/23 4:38:32 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PTCT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EXEC. VP AND CLO Boulding Mark Elliott sold $202,958 worth of shares (2,812 units at $72.18) as part of a pre-agreed trading plan and exercised 2,812 shares at a strike of $25.69 (SEC Form 4)

    4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)

    5/19/26 5:20:05 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF EXECUTIVE OFFICER Klein Matthew B. sold $917,154 worth of shares (12,572 units at $72.95) and was granted 12,500 shares, decreasing direct ownership by 0.02% to 393,998 units (SEC Form 4) to satisfy tax liability

    4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)

    5/15/26 5:20:06 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EXEC. VP AND CLO Boulding Mark Elliott exercised 3,540 shares at a strike of $46.54 and sold $279,570 worth of shares (3,540 units at $78.97) as part of a pre-agreed trading plan (SEC Form 4)

    4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)

    5/12/26 5:20:06 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PTCT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 14, 2024 - FDA Approves First Gene Therapy for Treatment of Aromatic L-amino Acid Decarboxylase Deficiency

    For Immediate Release: November 14, 2024 The U.S. Food and Drug Administration approved Kebilidi (eladocagene exuparvovec-tneq), an adeno-associated virus vector-based gene therapy indicated for the treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency. Kebilidi is the first FDA-approved gene therapy for treatment of AADC deficiency. “Clinical advancements in the f

    11/14/24 8:50:18 AM ET
    $CLPT
    $PTCT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $PTCT
    Financials

    Live finance-specific insights

    View All

    PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

    – First quarter 2026 total revenue of $273 million, including $226 million of product revenue, supporting full-year 2026 guidance raise –   – Global Sephience™ (sepiapterin) launch momentum continues with first quarter 2026 revenue of $125 million, representing 36% quarter-over-quarter growth – – Positive topline results from 24-month interim analysis of PIVOT-HD extension study of votoplam, supporting ongoing global Phase 3 INVEST-HD study and potential regulatory interactions – – Open-label vatiquinone registration study to be initiated in Q3 2026 based on FDA feedback –WARREN, N.J., May 7, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ:PTCT) today announced a corporate update and fi

    5/7/26 4:01:00 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PTC Therapeutics Reports Positive Topline Results from Month 24 Interim Analysis of PIVOT-HD Extension Study of Votoplam

    - Dose-dependent benefit on cUHDRS in Stage 2 participants compared to matched natural history cohort, with 52% slowing at 10 mg dose -- Continued evidence of favorable safety profile - - Novartis initiated global Phase 3 INVEST-HD study of votoplam -- PTC will host a conference call to discuss results today, April 28, at 4:30 pm ET - WARREN, N.J., April 28, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today reported positive topline results from the 24-month interim analysis of the PIVOT-HD long-term extension study, with favorable dose-dependent effects on disease progression for Stage 2 Huntington's disease (HD) patients following 24 months of votoplam treatment compared to a

    4/28/26 4:05:00 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PTC Therapeutics to Report Results from PIVOT-HD Long Term Extension Study

    WARREN, N.J., April 28, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) will host a webcast conference call today, April 28 at 4:30 p.m. ET to share results from the 24-month interim analysis of the PIVOT-HD long-term extension study of votoplam. PTC's partner Novartis stated on its quarterly earnings call today that long-term extension data are supportive of the now-initiated Novartis Phase 3 INVEST-HD study and Novartis and PTC will assess potential best next steps for the program including further actions with FDA. To access the live webcast, please visit the "Events & Presentations" page within the Investors section of the PTC website. A replay of the webcast will be available

    4/28/26 9:28:00 AM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PTCT
    Leadership Updates

    Live Leadership Updates

    View All

    PTC Therapeutics Appoints Biotech Banking Pioneer Jessica Chutter to Board of Directors

    WARREN, N.J., March 25, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ:PTCT) today announced the appointment of Jessica Chutter to its Board of Directors. Ms. Chutter is a highly accomplished biotechnology investment banker with an extensive list of achievements over her long tenure at Morgan Stanley, including building and leading the bank's biotechnology franchise.  "I have closely followed Jessica's illustrious career, and I am proud to welcome her to PTC's Board of Directors," said Michael Schmertzler, Chairman of the Board of Directors. "Jessica will play an integral role as the Board continues to work with the management team on charting the company's next stage of growth."Ms. Ch

    3/25/26 8:30:00 AM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors

    PONTE VEDRA, Fla., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation therapy, today announced the appointment of Lee Scott Golden, M.D., to its Board of Directors, effective immediately. Dr. Golden will serve as an independent director. Dr. Golden currently serves as Executive Vice President and Chief Medical Officer at PTC Therapeutics, Inc. (NASDAQ:PTCT), where he leads global clinical development across a broad rare disease pipeline. Before joining PTC, Dr. Golden served as the Chief Medical Officer at Espero BioPharma, Inc., a development-stage card

    12/1/25 9:00:00 AM ET
    $CVKD
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sandisk Set to Join S&P 500; Upwork, First Interstate BancSystem, PTC Therapeutics to Join S&P SmallCap 600

    NEW YORK, Nov. 24, 2025 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P SmallCap 600:  S&P SmallCap 600 constituent Sandisk Corp. (NASD: SNDK) will replace The Interpublic Group of Companies Inc. (NYSE:IPG) in the S&P 500, and PTC Therapeutics Inc. (NASD: PTCT) will replace Sandisk in the S&P SmallCap 600 effective prior to the opening of trading on Friday, November 28. S&P 500 constituent Omnicom Group Inc. (NYSE:OMC) is acquiring The Interpublic Group of Companies in a deal expected to close soon, pending final conditions.Upwork Inc. (NASD: UPWK) will replace Premier Inc. (NASD: PINC) in the S&P SmallCap 600 effective prior to the open of trading

    11/24/25 6:01:00 PM ET
    $FIBK
    $GIL
    $HBI
    Major Banks
    Finance
    Apparel
    Consumer Discretionary

    $PTCT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by PTC Therapeutics Inc.

    SC 13G/A - PTC THERAPEUTICS, INC. (0001070081) (Subject)

    11/14/24 5:22:11 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by PTC Therapeutics Inc.

    SC 13G/A - PTC THERAPEUTICS, INC. (0001070081) (Subject)

    11/8/24 10:52:39 AM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by PTC Therapeutics Inc.

    SC 13G/A - PTC THERAPEUTICS, INC. (0001070081) (Subject)

    10/18/24 10:57:11 AM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care